Get a proposal

THYROID CANCER · White paper

Thyroid Cancer Clinical Trials

Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.

Indication overview

About thyroid cancer — and why its trials are hard

Thyroid cancer is the most common endocrine malignancy, with an estimated 586,000 new cases globally in 2020 and roughly 43,720 US diagnoses annually. Most cases are differentiated (papillary and follicular) carcinomas with excellent prognoses, but medullary (RET-driven) and anaplastic subtypes are far more aggressive, the latter with under 10% five-year survival. Surgery plus radioactive iodine (RAI) and lifelong levothyroxine with TSH suppression form the backbone of care for differentiated disease. For RAI-refractory and advanced tumors, molecularly targeted tyrosine kinase inhibitors dominate: sorafenib (DECISION) and lenvatinib (SELECT) in differentiated thyroid cancer, cabozantinib in medullary and later differentiated disease, and highly selective RET inhibitors such as selpercatinib for RET-altered tumors. For BRAF V600E-mutant anaplastic thyroid cancer, dabrafenib plus trametinib provided the first effective systemic option. Trials rely on progression-free survival and objective response rate (RECIST) as primary or accelerated-approval endpoints, with overall survival often confounded by placebo crossover. Persistent challenges include mutation heterogeneity, radiological assessment variability, and late-stage recruitment difficulty.

Indication
Thyroid Cancer
ICD-10-CM
C73 — Malignant neoplasm of thyroid gland

Approved therapies & pivotal evidence

What's been approved — and by how much it moved the endpoint

Drug (brand)ApprovedSettingPivotal trialPrimary endpointMagnitude of benefit
Lenvatinib (Lenvima) 2015Progressive, radioiodine-refractory differentiated thyroid cancerSELECT (NCT01321554)Progression-free survival (PFS)Median PFS 18.3 vs 3.6 months (HR 0.21, p<0.001); ORR 65% vs 2%
Sorafenib (Nexavar) 2013Progressive, radioiodine-refractory differentiated thyroid cancerDECISION (NCT00984282)Progression-free survival (PFS)Median PFS 10.8 vs 5.8 months vs placebo (HR ~0.59)
Cabozantinib (Cometriq (MTC) / Cabometyx (DTC)) 2012Metastatic medullary thyroid carcinoma (Cometriq, 2012); RAI-refractory differentiated thyroid cancer (Cabometyx, 2021)EXAM (NCT00704730); COSMIC-311 (DTC)Progression-free survival (PFS)EXAM median PFS 11.2 vs 4.0 months (HR 0.28, p<0.0001); partial response 27% vs 0%
Selpercatinib (Retevmo) 2020RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancerLIBRETTO-001 (NCT03157128)Objective response rate (ORR) and duration of responseRET-mutant MTC ORR 69% (pretreated) and 73% (treatment-naive); durable responses
Dabrafenib + trametinib (Tafinlar + Mekinist) 2018BRAF V600E-mutant unresectable or metastatic anaplastic thyroid cancerROAR basket study (NCT02034110)Objective response rate (ORR)ORR approximately 56-61% in a subtype historically without effective systemic therapy
Levothyroxine (TSH suppression) (Synthroid and others) Standard of care (long established)Post-thyroidectomy hormone replacement and TSH-suppression to reduce recurrence in differentiated thyroid cancerStandard-of-care; established through clinical practice guidelinesRecurrence risk reduction; biochemical TSH controlTSH suppression reduces recurrence risk in high-risk differentiated thyroid cancer (magnitude per risk-stratified guidelines)

Where trials have failed

Drugs that missed their endpoint — and what contributed

The most instructive lessons in thyroid cancer development come from programmes that failed the endpoint that mattered.

Drug / trialEndpoint outcomeWhat contributed
Vandetanib — Advanced papillary thyroid cancer trial (NCT01876784)Limited clinical benefit with inconsistent responses; PFS gains not statistically significant in PTCInadequate molecular patient selection; underscored the need for biomarker-driven enrollment
Donafenib — NCT02960182Early termination due to a concerning toxicity profile (hepatotoxicity, hypertension)Sorafenib-derivative off-target effects; drove emphasis on more selective next-generation TKIs
PLX8394 — NCT02428712Limited efficacy in non-BRAF tumors and non-durable responses even in BRAF-positive diseaseMutation-specific activity without adequate stratification; highlighted need for combination strategies

Choosing the right endpoint

Primary endpoints that matter in thyroid cancer trials

  • Progression-free survival (PFS) — Common primary endpoint in advanced/RAI-refractory disease; depends on consistent RECIST imaging
  • Overall survival (OS) — Gold standard but frequently confounded by placebo crossover (e.g., 83% crossover in SELECT) and long follow-up
  • Objective response rate (ORR) — RECIST-based surrogate supporting accelerated approval, especially for RET and BRAF-targeted agents
  • Duration of response (DoR) — Captures durability of targeted-therapy responses; limited early data can reduce reliability
  • Quality of life (EORTC QLQ-C30 / FACT-G) — Increasingly weighted in regulatory decisions for incurable advanced disease

How iNGENū runs thyroid cancer trials

Physician-led design, built for FDA submission

Endpoint & biomarker strategy

Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.

FDA-ready data

Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.

Faster, lower-cost delivery

~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.

PDF
Advancing Thyroid Cancer Research
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Download white paper

Frequently asked questions

Thyroid Cancer clinical trials — FAQs

What is the standard treatment for differentiated thyroid cancer?
Surgery (total thyroidectomy or lobectomy) followed by radioactive iodine (RAI) ablation for residual tissue and micrometastases, plus lifelong levothyroxine, with TSH-suppression therapy in higher-risk patients to lower recurrence. Targeted tyrosine kinase inhibitors such as lenvatinib and sorafenib are reserved for progressive, RAI-refractory disease.
How are targeted therapies matched to thyroid cancer subtypes?
Molecular profiling drives selection: RET alterations in medullary and RET-fusion cancers are treated with selective RET inhibitors like selpercatinib, and BRAF V600E-mutant anaplastic thyroid cancer responds to dabrafenib plus trametinib. Multikinase inhibitors (lenvatinib, sorafenib, cabozantinib) target angiogenesis in RAI-refractory differentiated and medullary disease.
Why is overall survival hard to demonstrate in thyroid cancer trials?
Differentiated thyroid cancers are often indolent with long survival, and pivotal trials commonly allow placebo patients to cross over to active drug at progression (for example, 83% crossover in the lenvatinib SELECT trial), which dilutes any survival difference. Consequently, progression-free survival and objective response rate are typically the primary or accelerated-approval endpoints.

Ready to discuss your thyroid cancer trial?

Talk to our physician-led team about an FDA-ready, cost-efficient trial design.

Request a proposal